Table 5.
Summary of CLL and DLBCL patients treated with SF1126.
| Pt# | History | Clinical response |
|---|---|---|
| 1 | 43 years F Del 17p CLL [Rai l] | LN Flare C1D1/C1D4 |
| [No Prior Rx] | Decrease Size of LNs (C1D8/C1D11;WCC (Dec 40%)Stable Disease (16 weeks) as best response | |
| 2 | 63 years M CLL [Rai IV] | LN Flare C1D1/C1D4 |
| [4Prior Rx] | WCC fluctuating | |
| 3 | 41 years F CLL [Rai l] | Severe Hypersensitivity Reactiona (C1D1/C1D4) |
| [2 Prior Rx] | Remarkable improvement in symptomsb | |
| 4 | 82 years M CLL [Rai IV] | LN Flare, Fluctuating in LN size & WCC |
| [2 Prior Rx] | Producing urinec | |
| Haemodialysis | Stable disease (8 weeks) on SF1126 converting to unconfirmed partial response with add'n of Rituximab (see Fig. 3)d | |
| 5 | 78 years M DLBCL (Non-GC) [4 Prior Rx] | >40% LN reductione, LN redness ablated |
a
Patient has a history of allergies and discontinued after two doses due to grade 2 symptoms resistant to premedication.
b
Patient suffered from odynophagia, dystonia and dysphagia but after 2nd SF1126 dose patient's oral performance noticeably improved allowing patient to eat and talk.
c
After four doses of SF1126 patient undergoing haemodialysis 3×/wk began producing new appreciable quantities of urine.
d
Patient taken off study due to pneumonia related issues, unconfirmed PR by decreased ALC, LN size and spleen size.
e
Patient taken off study at end of C1 due to a non-drug related mechanical fall requiring hospitalisation.